- Research Article
- 10.1016/j.jad.2026.121387
Accelerated brain aging in prolonged grief disorder of later life: Influence of comorbid depression.
- Jun 01, 2026
- Journal of affective disorders
- Gyujoon Hwang + 5 more +5
Publications from 2021 to 2026
Showing 10 of 36,287 papers
Accelerated brain aging in prolonged grief disorder of later life: Influence of comorbid depression.
Tailoring of a chronic pain self-management intervention for individuals with opioid use disorder in office-based addiction treatment.
Sleeping Less Than Usual Is Associated With Greater Daily Depression and Higher Reactivity to Negative Interpersonal Events Among Suicidal Adolescents.
Changes in sleep can impact cognitive and emotional functioning and may contribute to depression. The current longitudinal study included a high-risk sample of adolescents and young adults with depression and/or suicidal thoughts and behaviors who were undergoing intensive outpatient treatment programs. We examined changes in sleep throughout treatment and whether daily changes in sleep impacted next-day depression through altered affective reactivity to interpersonal situations. Participants (N = 198, ages 13-23, 82% White, 76% female sex at birth) were recruited from intensive treatment programs for depression and suicide risk. Participants wore an actigraph and completed daily ratings of depression, sleep, and positive and negative reactivity to interpersonal events throughout treatment (M = 60 days, SD = 22 days). Clinicians rated weekly depression severity. Multilevel models tested changes in sleep and depression throughout treatment and examined daily relationships between total sleep time (TST), next-day depression, and affective reactivity. Multilevel mediation tested whether increased affective reactivity mediated daily relationships between TST and depression. Throughout treatment, self-reported TST increased (b = 0.01; p < .001) and daily self-reported depression severity decreased (b = -0.06; p = .02), although actigraphy-assessed TST did not change (b = 0.01; p = .16). Sleeping less than usual on diaries (b = -0.29; p = .02) but not actigraphy when controlling for covariates (b = -0.19; p = .18) was related to worse next-day depression. Greater clinician-rated depression severity amplified the effects of short TST on next-day depression for both diary (b = -0.22; p = .03) and actigraphy-assessed TST (b = -0.32; p = .01). Increased negative affectivity statistically mediated daily associations between short TST and increased next-day depression (indirect effects: B = 0.03; p < .001). Short sleep may contribute to depression through increased negative affectivity to interpersonal events. Future work should test whether sleep interventions in high-risk samples hastens symptom improvement.
Read moreSocial context in motion: The effects of personality traits on the dynamic links between interpersonal processes and suicidal ideation.
Suicidal ideation (SI) is dynamic and closely tied to social context, yet most work treats these links as static or unidirectional. We tested a transactional account whereby SI and interpersonal appraisals co-evolve over hours and examined personality trait moderators. Young adults receiving behavioral treatment who endorsed SI and/or suicidal behavior in the past four months (N=140) completed 21 days of ecological momentary assessment (7 prompts/day). At each prompt, participants reported current SI and rated interpersonal strain (rejection/criticism/exclusion/stress) and enrichment (enjoyment/connection/meaning/support) from interpersonal interactions. Dynamic structural equation models estimated five features of SI: reactivity, generation, inertia, instability, and intensity. Negative Affectivity, Detachment, and Disinhibition trait domains were tested as moderators. Interpersonal strain was associated with higher subsequent SI (reactivity), and higher SI was associated with higher subsequent strain (generation). Likewise, interpersonal enrichment was associated with lower subsequent SI, and higher SI was associated with lower subsequent enrichment. Detachment uniquely moderated these dynamic processes: higher Detachment was associated with larger SI increases after strain and larger SI decreases after enrichment, as well as higher SI intensity and instability, higher strain, and lower enrichment. Facet models indicated that Anhedonia concentrated Detachment-related risk (higher mean SI, higher strain intensity and instability, lower enrichment, higher SI inertia and instability, and stronger reactivity to strain/enrichment). In contrast, Intimacy Avoidance was associated with lower strain instability and lower enrichment intensity. Negative Affectivity and Disinhibition did not moderate dynamic paths. SI was linked to interpersonal appraisals through short-cycle, bidirectional associations that were moderated by Detachment, especially its Anhedonia facet.
Read moreAnalyzing the Purposes and Mechanisms of Faculty Cluster Hiring Initiatives to Promote Racial Equity
ABSTRACT Since the Supreme Court’s 2023 ruling against race-conscious admissions, anti-diversity, equity, and inclusion efforts have grown, creating challenges for leaders committed to advancing racial equity on their campuses. Using racialized change work as a lens, we analyze faculty cluster hiring as a potential strategy toward racial equity that could hold up in the current political climate. This study uses data from four historically white research universities, focusing on how leaders used faculty cluster hiring as a strategy to promote racial equity. Our findings reveal that cluster hire leaders leveraged racialized expertise as hiring capital, creating a “strategic side door” to diversify faculty demographics while sidestepping risks associated with affirmative-action-like approaches. Cluster hire leaders also leveraged faculty lines to challenge — or attempt to challenge — practices that sustain a racist status quo. However, this approach could also create additional racialized labor expectations on newly hired Faculty of Color. We offer recommendations for leaders to consider when designing and implementing cluster hiring initiatives to support racial equity effectively.
Read moreA Phase 3 Trial of Brepocitinib in Dermatomyositis
BackgroundBrepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis.MethodsIn this phase 3, double-blind, randomized, placebo-controlled trial, adults with dermatomyositis were assigned in a 1:1:1 ratio to receive once-daily oral brepocitinib at a dose of 30 mg, brepocitinib at a dose of 15 mg, or placebo for 52 weeks. Standard therapies were continued, and glucocorticoids were tapered. The primary end point was the Total Improvement Score, a validated composite myositis index (with scores ranging from 0 to 100 and higher scores indicating greater improvement) at week 52. Key secondary end points, including skin disease activity, glucocorticoid tapering, and physical function, were tested in a multiplicity-controlled sequence.ResultsA total of 241 patients underwent randomization: 81 to receive brepocitinib 30 mg, 81 to receive brepocitinib 15 mg, and 79 to receive placebo. At week 52, the mean Total Improvement Score was 46.5, 37.5, and 31.2, respectively (difference with brepocitinib 30 mg vs. placebo, 15.3; 95% confidence interval [CI], 6.7 to 24.0; P<0.001; difference with brepocitinib 15 mg vs. placebo, 6.3; 95% CI, −2.4 to 14.9). Brepocitinib 30 mg was superior to placebo across all nine key secondary end points, including skin disease activity, systemic glucocorticoid tapering, and functional disability, with improvements observed as early as week 4. Serious infections were more frequent in the brepocitinib 30-mg group than in the placebo group (10% vs. 1%). No deaths occurred during the trial.ConclusionsIn adults with dermatomyositis that was resistant to previous therapy, the use of brepocitinib at a dose of 30 mg (but not at a dose of 15 mg) resulted in significant benefits with respect to a composite myositis index, skin disease severity, glucocorticoid tapering, and functional disability. (Funded by Priovant Therapeutics; ClinicalTrials.gov number, NCT05437263.)
Read moreRisk Factors Associated with Longitudinal Trajectories of Mania Symptoms in Youth.
Mania symptoms in youth predict poor long-term mental health outcomes, yet their developmental trajectories and associated risk factors remain unclear. Leveraging data from the Adolescent Brain Cognitive Development Study (N=10,474; 9-10 years at baseline; 48% female, 65% white), we used latent growth mixture models to identify trajectories of mania symptoms across two years in early adolescence. We used multinomial logistic regressions to examine associations between trajectories and risk factors across mental and physical health, cognition, and family/environmental domains. We identified three trajectories: Low (58%), Moderate (32%), and High/Variable Mania Symptoms (10%). All mental health symptoms (depression, attention deficit hyperactivity disorder, conduct and oppositional defiant disorders and anxiety), two physical health factors (sleep disturbances, irritable bowel syndrome symptoms), one cognitive factor (verbal learning impairment), and three family/environmental factors (trauma, parent- and youth-reported family conflict) significantly differentiated between all three trajectories, reflecting incremental increases in risk factor severity with increasing mania symptoms. Other physical, cognitive, family and environmental factors were also associated with more severe mania symptom trajectories. More severe mania symptom trajectories in early adolescence are associated with multiple mental, physical, cognitive, family and environmental risk factors, underscoring the need for comprehensive risk prediction approaches in youth.
Read moreDifferentiation of macular atrophy secondary to neovascular age-related macular degeneration vs. de novo geographic atrophy: a multimodal analysis.
To compare macular atrophy following neovascular age-related macular degeneration (nAMD) vs. geographic atrophy (GA) following dry AMD. We analysed 60 eyes from 44 patients: 30 eyes with de novo GA and 30 with macular atrophy secondary to nAMD. All patients had monthly follow-ups before GA onset and continued for at least two years after. GA was defined as complete retinal pigment epithelium atrophy ≥250 μm using OCT scans. OCT biomarkers at GA onset, including central macular thickness (CMT), subfoveal choroidal thickness (SFCT), epiretinal membrane (ERM), double-layer sign (DLS), subretinal hyperreflective material (SRHM), hyperreflective foci (HRF), outer retinal tubulation (ORT), and intraretinal fluid (IRF), were assessed. Chi-square test, Spearman correlation, and linear mixed models were used. The mean age was 80.06 ± 8.60 years, with 50.0% male. Eyes with nAMD progressed to macular atrophy after 31.38 ± 30.72 months and 8.86 ± 10.84 anti-vascular endothelial growth factor (VEGF) injections. Compared to de novo GA, eyes with macular atrophy following nAMD had larger baseline atrophic area (3.791 ± 2.661 mm² vs. 1.115 ± 0.951 mm²; P < 0.001) and greater atrophy growth (2.646 ± 2.014 mm² vs. 0.652 ± 0.722 mm²; P < 0.001), with more frequent ERM, DLS, HRF, SRHM, ORT, and IRF. Atrophy growth correlated with baseline SFCT (r = -0.545, P = 0.002) and GA area (r = 0.501, P = 0.005) but not with the number of anti-VEGF injections (p > 0.05). Eyes with macular atrophy secondary to nAMD exhibit larger initial atrophic areas and faster progression compared to de novo GA. OCT biomarkers may detect previous exudation, helping identify cases where recently FDA-approved GA therapies may be relatively contraindicated due to prior disease.
Read moreTHE "SCOLEX" SIGN: A Distinct Hyperreflective Foci on the Wall of Serous Pigment Epithelial Detachments in Central Serous Chorioretinopathy - Micron Report Number Seven.
To describe a novel optical coherence tomography finding called "scolex sign" in cases of central serous chorioretinopathy. This retrospective multicenter study included patients with central serous chorioretinopathy with serous pigment epithelial detachments (PEDs) greater than 100 µ m, with or without subretinal fluid. Eyes showing a distinct hyperreflective focus on the PED wall (scolex sign) were analyzed. An equal number of age-matched controls with PEDs but without the scolex sign were included. Multimodal imaging data were reviewed. A subgroup analysis based on subretinal fluid status was also performed. Of 291 eyes with large serous PEDs, 52 eyes exhibited the "scolex sign" and were compared with 52 age-matched controls. Baseline characteristics including sex, systemic comorbidities, best-recorded visual acuity and optical coherence tomography parameters were similar in both the groups. However, eyes with the "scolex" sign exhibited a greater number of central PEDs and shorter distance from the foveal center. On follow-up, eyes with the "scolex" sign showed a higher rate of PED flattening and subretinal fluid resolution trended to be higher compared with controls. The "scolex" sign represents a novel, benign optical coherence tomography feature seen in a subset of central serous chorioretinopathy cases. While not associated with poorer outcomes or adverse sequelae, it may reflect ongoing reparative changes, indicating a resolving stage of the disease.
Read moreProtocol for a randomized trial of a scalable, interactive tool to support surrogate decision-makers of critically ill patients.
Patients, particularly those at the end of their lives, frequently receive goal-discordant care, and their surrogate decision-makers suffer long-term psychological injury. Contributors to these issues may include infrequent communication between clinicians and surrogates, failure to discuss prognosis, values, and treatment options that include comfort-focused care, and surrogates facing high-stakes decision-making while underprepared and overwhelmed psychologically and emotionally. This is a multicenter, patient-randomized efficacy trial of a multi-component intervention, versus usual care, for 370 incapacitated, critically ill adults at high risk of death or severe disability, and their surrogate decision-makers, from 7 hospitals across the United States. The intervention combines surrogate utilization of a digital Family Support Tool (FST) in real-time during their loved one's hospitalization with proactively scheduled family meetings, for which both surrogates and clinicians receive additional preparation, at set intervals during the ICU hospitalization. Those in the control arm will receive usual ICU care. Our primary outcome is patient-centeredness of care, measured using the modified Patient Perceived Patient-Centeredness of Care (PPPC) scale. Secondary outcomes include surrogates' psychological symptom burden, communication and decision quality, and patients' health resource utilization and clinical outcomes. This trial will provide robust evidence about the impact of combining the FST with increased and intentional communication, on patient, family, and health system outcomes for those hospitalized in the ICU.
Read more